Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

GSK-923295

Alternative Names: gsk-923295, gsk923295, gsk 923295
Latest Update: 2023-12-29
Latest Update Note: PubMed Publication

Product Description

anti-mitotic compound for refractory cancers (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00504790)

Mechanisms of Action: CENP-E Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Hodgkin Lymphoma|Gastrointestinal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CPE107602

P1

Completed

Hodgkin Lymphoma|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Gastrointestinal Cancer

2012-05-07

Recent News Events

Date

Type

Title

12/29/2023

PubMed

 Maximizing Anticancer Response with MPS1 and CENPE Inhibition Alongside Apoptosis Induction.

09/20/2023

PubMed

 CTCF is essential for proper mitotic spindle structure and anaphase segregation.

12/28/2021

PubMed

 Functional Assessment of Kinesin-7 CENP-E in Spermatocytes using In Vivo Inhibition, Immunofluorescence and Flow Cytometry.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions